Lucerne, Switzerland 
contact@nemooai.com
“TOWARDS CURE” (CR) FOR MOST PATIENTS
Targeting far higher levels of efficacy in cancer care
We stay very disciplined in our thinking and assumptions about what our significant, expected contributions can be – we re-evaluate and learn constantly (AI). We use AI extensively. We go deep, decide from data (AI), creativity, KOL experiences, spiritual understanding of tumours, apply human judgment science based, add medical and risk return parameters financially – optimise it all – and go for it !
CLINICAL & TIME TO MARKET
We do the setups (AI) and financing, consult with EMA and FDA upfront. We run clinical in smartest ways (AI), low costs (Parexel adaptive trials). 18-24 months ahead, we plan launches, deals or exits
Introduction to AMEDIOO Health EDC
“We work where we work best.”
We own an independent and thorough understanding of our technologies from the University of Vienna managed by ETH Zurich and experienced management, applying AI driven intelligence in immunology to transform key sectors of care moving “closer to cure” (CR) or “cure”
various tissues & cancer types
high medical need & lack of options (EDC)
major cancer types with improvements
Ambition is to reach “cure” (CR/R) for most patients
27
YEARS
OF SCIENTIFIC, CLINICAL WORK,
NIH GRANTS
“TOWARDS CURE” (CR) FOR MORE PATIENTS
Higher efficacy in
15 selected cancer types
We only work where our products and technologies work best. We focus inside areas on synergies to reduce costs and risk. We use AI and regulatory advise (FDA, EMA) extensively. It is a “unique, simple and powerful approach” to deliver breakthroughs, our “best “shots and skills” towards “curing cancer“
Amedioo ® Pelvic
We perceive the gaps to cure closable and aim at far higher efficacy rates (CR) in:
. P1 Vulva Cancer
. P2 Vaginal Cancer
. P3 Penile Cancer
. P4 Ovarian Cancer
. P5 Colorectal Cancer
. P6 Cervical Cancer
. P7 Anal & Rectal Cancer
Amedioo ® Thorax
We perceive the gaps to cure closable and aim at far higher efficacy rates (CR) in:
. T1 Lung Large Cell Carcin.
. T2 Lung nodules cancer
. T3 NSC adenocarcinoma
. T4 NSC squamous CC
. T5 SCLC small CC
. T6 SCLC combined SCC
.
Amedioo ® Rare (Swiss Orphan®.com)
We perceive the gaps to cure closable and aim at far higher efficacy rates (CR) in rare cancers:
. R1 = P1
. R2 = Liposarcomas
. R3 = P3
. R4 = P4
. R5 = P7
. R6 = Mesoteliomas
As therapies for rare cancers follow different regulatory paths and strategies, we put them into special bag:
swissorphan.com
MAJOR CANCER INDICATIONS
We focus and separated
out other major indications
We only work where our products and technologies work best. We also try to “crack the nuts” of the biggest challenges in oncology: pancreatic cancer (PC), non small cell lung cancer (NSCLC) and melanoma in humans (skin cancer, see annimoo.com) under a breakthrough in human cancers’ company, “meedioo.com”. Still exploratory today (2023-25), they represent later, ethical options
EDC – Ethics Driven Companies
We aspire to assure end-to-end financing for our indications by NEMOO AI, with reviews & financial value updates
As part of EDC companies, we were developed by NEMOO AI Value Builders EDC AG. We continue to benefit from their support and coaching, their structure, networks and governance. We jointly develop our projects, people, teams, indications, new breakthrough products and add simple AI solutions for doctors where needed. We meet for future growth opportunities, creatively, selectively and often
Best Experience
Our team is very solid, science, development, medical, launches and finance
Capital
We partner closely with investors, their goals, to create more value together
For Further Information:
contact@
nemooai.com
NEMOO AI Value Builders EDC AG is the founding partner and supporting us on corporate matters and finance.
LEADERSHIP & GOVERNANCE
Experienced Team
We follow the medicine, science and focus on solid, risk reduced returns.
Our core team combines a variety of backgrounds and skills, deep practical and operational experience from drug development (Parexel), regulatory affairs (Parexel), pharmaceuticals (Roche, Biogen, AstraZeneca) and biotechnology (Amgen, Biogen), manufacturing (Lonza), scientific & clinical development (NovoNordisk, Roche, Parexel), corporate finance (SP, Merck) and general management (Roche, AZ, Biogen, Cubist, Sobi)
We are positively “driven” with “passion” towards curing cancer
Sara, Christian